A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Trial Profile

A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Glibenclamide (Primary)
  • Indications Oedema; Stroke
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms GAMES-RP
  • Sponsors Remedy Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results (n=77) assessing prespecified adjudicated edema endpoints presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 24 Feb 2017 Results of subgroup analysis of patients with Large Hemispheric Infarction (n=65) presented at the 42nd International Stroke Conference
    • 06 Jul 2016 Newly analyzed data from 12-month follow-ups of patients in this trial will be published in the second quarter 2016 report, according to a Remedy Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top